
ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases
ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop




